@article {HegenP5.356作者={哈拉尔德Hegen珍妮Walde和迈克尔·奥尔和Gabriel Bsteh Franziska Di泡利和Florian Deisenhammer和托马斯·伯杰},title ={疾病修饰治疗影响的纵向演化anti-JCV抗体在多发性硬化指数(P5.356)},体积={90}={15}补充数量,elocation-id = {P5.356} ={2018},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={摘要目的:探讨疾病修饰治疗的影响(DMT)的纵向演化anti-JC-virus (JCV)抗体指数(AI)。首页背景:风险natalizumab-related渐进多焦点的脑白质病与anti-JCV抗体的存在。最近的研究声称,anti-JCV AI随natalizumab疗法。设计/方法:多发性硬化(MS)患者的女士因斯布鲁克医科大学的中心,人血清采样的时间间隔4 {\ textendash} 6年6 {\ textpm} 3个月,包括在这个回顾性研究如果下列(额外的)标准之一了:(a)开始与β干扰素或glatiramer醋酸或(B) natalizumab治疗观察期间至少有一个血清样本可用治疗前后启动或(C)没有DMT政府在观察期内。Anti-JCV抗体血清学地位和指数由两步第二代Anti-JCV抗体测定。结果:共有92名患者被纳入研究。平均随访时间为54.4个月,平均9纵收集每个病人样本可用。75(81.5 \ %)患者并没有改变anti-JCV抗体状态观察期间,而4.1 \ %的患者有或{\ textendash}每年恢复。使用一个混合模型,没有显著改变纵向anti-JCV AI进化比较前的一小段时间内,要么β干扰素治疗开始后,glatiramer醋酸或natalizumab。在这些患者稳定anti-JCV抗体状态随着时间的推移,纵向变异anti-JCV AI范围从10 {\ textendash} 15 \ %和患者相似,没有不同。结论:Anti-JCV AI不会受到政府β干扰素,glatiramer醋酸或natalizumab证明——第一次——通过纵向研究设计包括之前以及之后样品DMT的开始。此外,变异anti-JCV AI似乎anti-JCV抗体开发的评价的关键。Study Supported by: BiogenDisclosure: Dr. Hegen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals Europe. Dr. Walde has nothing to disclose. Dr. Auer has nothing to disclose. Dr. Bsteh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Teva. Dr. Di Pauli has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen. Dr. Deisenhammer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme-Sanofi, Merck, Novartis, Roche, TEVA-Ratiopharm. Dr. Berger has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from Almirall, Biogen, Celgene, Genzyme, Merck, Novartis, Octapharma, Roche, Sanofi Adventist/TEVA. Dr. Berger has received research support from His institution has received financial support by unrestricted research grants (Biogen, Novartis, Roche, Sanofi Aventis/TEVA) and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, Merck, Novartis, Octapharma,.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/90/15_Supplement/P5.356}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }